Igor Shuryak1, David J Carlson2, J Martin Brown3, David J Brenner4. 1. Center for Radiological Research, Columbia University, New York, USA. 2. Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, USA. 3. Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University, USA. 4. Center for Radiological Research, Columbia University, New York, USA. Electronic address: djb3@cumc.columbia.edu.
Abstract
BACKGROUND AND PURPOSE: Two aspects of stereotactic radiotherapy (SRT) require clarification: First, are tumoricidal mechanisms at high-doses/fraction the same as at lower doses? Second, is single high-dose SRT treatment advantageous for tumor control (TCP) vs. multi-fraction SRT? MATERIAL AND METHODS: We analyzed published TCP data for lung tumors or brain metastases from 2965 SRT patients, covering a wide range of doses and fraction numbers. We used: (a) a linear-quadratic model (including heterogeneity), which assumes the same mechanisms at all doses, and (b) alternative models with terms describing distinct tumoricidal mechanisms at high doses. RESULTS: Both for lung and brain data, the LQ model provided a significantly better fit over the entire range of treatment doses than did any of the models requiring extra terms at high doses. Analyzing the data as a function of fractionation (1 fraction vs. >1 fraction), there was no significant effect on TCP in the lung data, whereas for brain data multi-fraction SRT was associated with higher TCP than single-fraction treatment. CONCLUSION: Our analysis suggests that distinct tumoricidal mechanisms do not determine tumor control at high doses/fraction. In addition, there is evidence suggesting that multi-fraction SRT is superior to single-dose SRT.
BACKGROUND AND PURPOSE: Two aspects of stereotactic radiotherapy (SRT) require clarification: First, are tumoricidal mechanisms at high-doses/fraction the same as at lower doses? Second, is single high-dose SRT treatment advantageous for tumor control (TCP) vs. multi-fraction SRT? MATERIAL AND METHODS: We analyzed published TCP data for lung tumors or brain metastases from 2965 SRT patients, covering a wide range of doses and fraction numbers. We used: (a) a linear-quadratic model (including heterogeneity), which assumes the same mechanisms at all doses, and (b) alternative models with terms describing distinct tumoricidal mechanisms at high doses. RESULTS: Both for lung and brain data, the LQ model provided a significantly better fit over the entire range of treatment doses than did any of the models requiring extra terms at high doses. Analyzing the data as a function of fractionation (1 fraction vs. >1 fraction), there was no significant effect on TCP in the lung data, whereas for brain data multi-fraction SRT was associated with higher TCP than single-fraction treatment. CONCLUSION: Our analysis suggests that distinct tumoricidal mechanisms do not determine tumor control at high doses/fraction. In addition, there is evidence suggesting that multi-fraction SRT is superior to single-dose SRT.
Authors: M Protopapa; V Kouloulias; A Kougioumtzopoulou; Z Liakouli; C Papadimitriou; A Zygogianni Journal: Clin Transl Oncol Date: 2019-06-28 Impact factor: 3.405
Authors: Yijun Ding; Harrison H Barrett; Matthew A Kupinski; Yevgeniy Vinogradskiy; Moyed Miften; Bernard L Jones Journal: Med Phys Date: 2019-06-07 Impact factor: 4.071
Authors: Feng Liu; An Tai; Percy Lee; Tithi Biswas; George X Ding; Isaam El Naqa; Jimm Grimm; Andrew Jackson; Feng-Ming Spring Kong; Tamara LaCouture; Billy Loo; Moyed Miften; Timothy Solberg; X Allen Li Journal: Radiother Oncol Date: 2016-11-18 Impact factor: 6.280
Authors: Jeho Jeong; Jung Hun Oh; Jan-Jakob Sonke; Jose Belderbos; Jeffrey D Bradley; Andrew N Fontanella; Shyam S Rao; Joseph O Deasy Journal: Clin Cancer Res Date: 2017-05-24 Impact factor: 12.531
Authors: Jordan A Torok; Patrick Oh; Katherine D Castle; Michael Reinsvold; Yan Ma; Lixia Luo; Chang-Lung Lee; David G Kirsch Journal: Cancer Res Date: 2018-10-12 Impact factor: 12.701